References
- Fricton JR , KroeningR , HaleyD , SiegertR. Myofascial pain syndrome of the head and neck: a review of clinical characteristics of 164 patients. Oral Surg Oral Med Oral Pathol.60(6), 615–623 (1985).
- Simons DG , TravellJG , SimonsLS. Myofascial Pain and Dysfunction: the Trigger Point Manual.FrostEAM (Ed.). Williams & Wilkins, MD, USA, 1664 (1999).
- Tough EA , WhiteAR , RichardsS , CampbellJ. Variability of criteria used to diagnose myofascial trigger point pain syndrome–evidence from a review of the literature. Clin. J. Pain23(3), 278–286 (2007).
- Giamberardino MA , AffaitatiG , FabrizioA , ConstantiR. Myofascial pain syndromes and their evaluation. Best Pract. Res. Clin. Rheumatol.25(2), 185–198 (2011).
- Couppe C , MidttunA , HildenJ , JorgensenU , OxholmP , Fuglsang-FrederiksenA. Spontaneous needle electromyographic activity in myofascial trigger points in the infraspinatus muscle: a blinded assessment. J. Musculoskelet. Pain9(3). 7–16 (2001).
- Li LQ , HuangT , WangYQet al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J. Med. Virol.92(6), 577–583 (2020).
- Morjaria JB , OmarF , PolosaR , GulliG , DalalPU , KaulS. Bilateral lower limb weakness: a cerebrovascular consequence of covid-19 or a complication associated with it?Intern. Emerg. Med.15, 901–905 (2020).
- Willi S , LütholdR , HuntAet al. COVID-19 sequelae in adults aged less than 50 years: a systematic review. Travel. Med. Infect. Dis.40, 101995 (2021).
- Saxena A , ChansoriaM , TomarG , KumarA. Myofascial pain syndrome: an overview. J. Pain Palliat. Care Pharmacothe.29(1), 16–21 (2015).
- Vernon H , SchneiderM. Chiropractic management of myofascial trigger points and myofascial pain syndrome. A systematic review of the literature. J. Manipulative Physiol. Ther.32(1), 14–24 (2009).
- Gerwin RD . Diagnosis of myofascial pain syndrome. Phys. Med. Rehabil. Clin. N Am.25(2), 341–355 (2014).
- Cummings TM , WhiteA. Needling therapies in the management of myofascial trigger point pain: a systematic review. Arch. Phys. Med. Rehabil.82(7), 986–992 (2001).
- Desai MJ , SainiV , SainiS. Myofascial pain syndrome: a treatment review. Pain Ther.2(1), 21–36 (2013).
- Malanga GA , GwynnMW , SmithR , MillerD. Tizanidine is effective in the treatment of myofascial pain syndrome. Pain Physician5(4), 422–432 (2002).
- Soares A , AndrioloRB , AtallahAN , da SilvaEM. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev.18(4), CD007533 (2012).
- Manjavachi MN , MottaEM , MarottaDM , LeiteDFP , CalixtoJB. Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice. Pain151, 345–355 (2010).
- Arunachalam PS , WimmersF , MokCKPet al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science369(6508), 1210–1220 (2020).
- Mathew D , GilesJR , BaxterAEet al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science369(6508), eabc8511 (2020).
- Fernández-de-las-Peñas C , Palacios-CeñaD , Gómez-MayordomoV , CuadradoML , FlorencioLL. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int. J. Environ. Res. Public Health18(5), 2621 (2021).
- Hu B , HuangS , YinL. The cytokine storm and COVID‐19. J. Med. Virol.93, 250–256 (2021).
- Ay MZ , PohCM , RéniaL , MacAryPA , NgLFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol.20(6), 363–374 (2020).